Antibodies for
Immunohistochemistry
CMV (8B1.2, 1G5.2 & 2D4.2)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45203 IMPATH CMV RTU M (8B1.2,1G5.2&2D4.2)
50 Tests
44278 CMV RTU M (8B1.2,1G5.2&2D4.2) RUO 7 ml Ready To Use
44578 CMV 0,1 M (8B1.2,1G5.2&2D4.2) RUO
100 µl liquid Concentrated
44579 CMV 1 M (8B1.2,1G5.2&2D4.2) RUO
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
CMV infected tissue
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
2a
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
CMV infection is usually seen in immunocompromised patients involving the GI tract, lung, heart, liver, and placenta among other organs. There
is no cross-reactivity with other herpesviruses or adenoviruses.
Reference
1. de la Hoz RE, et al. J Clin Virol. 2002; 25:S1-S12.
2. Bronsther O, et al. J Med Virol. 1988; 24:423-434.
3. Drummer JS, et al. J Infect Dis. 1985; 152:1182-1191.
4. Anwar F, et al. Ann Diag Pathol. 1999; 3:19-22.
5. Cote L, et al. J Clin Microbiol. 1993; 31:2066-2069.
6. Sheehan MM, et al. Cytopathology. 1998; 9:29–37.
7. Saetta A, et al. Virchows Arch. 1998; 432:159-162.
8. Solans EP, et al. Diagn Cytopath. 1997; 16:350-352.
9. Colina F, et al. J Clin Pathol. 1995; 48:351-357.
10. Rimsza LM, et al. Am J Clin Pathol. 1996; 106:544-548.
11. Kandiel A, et al. Am J Gastroenterol. 2006; 101:2857-2865.
12. Kambham N, et al. Am J Surg Pathol. 2004; 28:365-373.
13. Ribalta T, et al. Virchows Arch. 2002; 440:166-171.
14. Cruz-Spano L, et al. Med Sci Monit. 2002; 8:BR230-BR235.
90
